Study Evaluating the Effect of TC-6499 on Gastric Emptying Time in Diabetic Subjects With Gastroparesis
Phase of Trial: Phase I/II
Latest Information Update: 15 May 2015
Price : $35 *
At a glance
- Drugs TC 6499 (Primary)
- Indications Diabetic gastroparesis
- Focus Therapeutic Use
- Sponsors Targacept
- 16 Apr 2015 According to a Targacept media release, status changed from active, no longer recruiting to completed.
- 16 Apr 2015 Top-line results published in the Media Release.
- 16 Apr 2015 Primary endpoint (The change in gastric emptying half-time determined for each treatment relative to placebo after single dose administration of study drug in each arm) has not been met, according to Targacept media release.